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S_inmary A novel "'In ligand (a C-functionalised derivative of 1,4,7-triazacyclononanetriacetic acid), termed
9N3, was covalently attached to chimeric B72.3, labelled with "'In and compared with ".In-labelled chimeric
B72.3 diethylenetriaminepentaacetic acid (DTPA) cyclic anhydnde conjugate (cDTPA) and a C-linked
derivative of DTPA (CT-DTPA) in athymic mice bearing human colon carcinoma xenografts. Significant
differences in biodistribution were observed between 9N3 and cDTPA conjugates especially in the tumour
uptake and blood, liver, femur and colon levels at 24, 48 and 144 h. Significantly higher tumour uptake was
observed for "'In-cB72.3-9N3 compared with "'.In-cB72.3-cDTPA at all time points. Radiolocalisation (RI)
indices increased with time for the 9N3 conjugate but remained constant for the cDTPA conjugate. The
biodistribution of "'In-labelled cB72.3-CT-DTPA was similar to that of ".In-labelled cB72.3-9N3 except for
elevated kidney levels. A 12N4 macrocycle (a C-functionalised derivative of 1,4,7,10-tetraazacyclododecanete-
traacetic acid) was also tested for its ability to chelate "'In and its biodistribution examined. Labelled
conjugates with this macrocycle were more difficult to prepare in a stable form but gave a very similar
biodistribution to the 9N3 macrocycle conjugate. Macrocycle-antibody conjugates of this type offer con-
siderable promise for tumour imaging in patients.
Many studies over recent years have shown that radiolabelled
antibodies to tumour-associated antigens can be successfully
used for imaging a variety of tumour types (Davidson et al.,
1991; Lamki et al., 1991; Goldenberg et al., 1993). Several
gamma-emitting radioisotopes have been used for tumour
imaging, with one of the most widely used being indium-l 1
("'In). "'In-labelled antibodies enjoy a number ofadvantages
over those labelled with other isotopes, including a favour-
able gamma energy for imaging (173 and 274 keV), a 2.8 day
half-life and the absence of specific mechanisms to remove
the isotope from the antibody, as is the case with the
deiodination of iodine-labelled antibodies.
Attachment of "'In to monoclonal antibodies requires the
use of a chelator, the most widely used for indium being
DTPA. DTPA is normally attached to antibody as the cyclic
anhydride, which results in the attachment through one of
the chelation arms (Hnatowich et al., 1983). The chelation of
"'In by conjugates of this type is relatively weak, and the use
of these in vivo has led to significant instability of the labelled
conjugate in both animal model studies and patients
(Hnatowich et al., 1985). This instability is particularly
manifested by the accumulation of high levels of "'In in the
liver (Shumacher et al., 1990), possibly as a result of release
of free "'In, which is then bound by serum transferrin and
transported to the liver (Meares et al., 1984). Recently, novel
bifunctional derivatives of DTPA have been devised in which
the carbon backbone of the chelate has a linking group
inserted for attachment to the antibody such that all eight
coordination sites on DTPA are preserved (Brechbiel et al.,
1986). These conjugates are more stable than those produced
with cDTPA, give rise to lower liver uptake in animals
(Roselli et al., 1989) and indeed have allowed imaging of
liver metastases in patients (Divgi et al., 1991).
There has also been considerable interest in the develop-
ment of macrocycic chelators for the attachment of radio-
isotopes to antibodies (Moi et al., 1988; Cox et al., 1989;
Craig et al., 1989; Deshpande et al., 1990). It has been shown
that the macrocycle 1,4,7-triazacyclononanetriacetic acid
(termed 9N3) can form very stable complexes with "'In (log
KI 26.2/H20, 298KI = 0.1) and the X-ray structure of the
indium complex has been solved (Broan et al., 1991). Bifunc-
tional derivatives of this macrocycle incorporating a male-
imide spacer arm have been synthesised for attachment to an
antibody without loss of any of the macrocycic chelation
capacity (Craig et al., 1989). This study was therefore under-
taken to determine the comparative in vivo behaviour of
"'In-9N3 conjugates with the relevant clinical control DTPA
and a bifunctional DTPA derivative using an antibody to a
tumour-associated antigen. The bifunctional DTPA
derivative used in this study was CT-DTPA (Harrison et al.,
1991).
In addition, we have developed a series of macrocycic
chelators for the attachment of the beta-emitting isotope
yttrium-90 to antibodies (Cox et al., 1989). One of these
(termed 12N4), has been shown to form stable complexes
with 9'Y that have superior biodistribution properties to
DTPA and bifunctional DTPA derivatives (Meares et al.,
1990; Harrison et al., 1991). This macrocycle is also capable
of forming a complex with "'In, and thus is also a candidate
for clinical use in imaging studies. This would allow the use
of the "'In-12N4 conjugate as a tracer for corresponding
9Y-12N4 conjugates, allowing accurate measurements of
radiation dosimetry from the same antibody preparation.
Therefore the biodistribution of "'In-12N4 conjugates has
also been compared with that of the 9N3 macrocycle.
The antibody selected for these studies was a recombinant
chimeric version of B72.3 (Whittle et al., 1987; Colcher et al.,
1989). B72.3 is a murne antibody which reacts with a
tumour-associated glycoprotein (TAG 72) found on a large
number of human neoplasms including colon, breast and
ovarian carcinomas. This antibody has been evaluated in
iodinated form in animals (Colcher et al., 1989; King et al.,
1992) and in patients (Begent et al., 1990; Khazaeli et al.,
1991).
Materis and methods
Preparation and characterisation ofchimeric B72.3
immuioconjugates
Chimeric B72.3 (15 mg ml'), prepared as described
previously (Colcher et al., 1989), was buffer exchanged into
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0.1M sodium hydrogen carbonate pH 8.0 containing 2 mM
EDTA, and was incubated with 2-iminothiolane hydro-
chloride (Sigma 1-6256; 1 mM) at 20C for 30min. Unreacted
reagent was removed by desalting the mixture on a pre-
packed Sephadex G-25 gel filtration column (PD-10, Phar-
macia) equilibrated in the same buffer. An aliquot was
removed for titration with 4,4'-dithiodipyridine (Sigma
D-8136; DTDP) to determine the number of thiols generated
(Lyons et al., 1990). This treatment typically introduced
1 thiol per chimeric B72.3. A malimide derivative of the
chelator [9N3 macrocycle (CT82, Figure 1), CT-DTPA
(CT74, Figure 1) or 12N4 macrocycle (C-177, Figure 1)] was
added to the modified chimeric B72.3 at a 10-fold molar
excess over the thiol concentration. The mixture was
incubated at 20-C for 60min and unreacted chelator
removed by desalting into 0.1 M sodium hydrogen carbonate
pH 8.0. Immunoconjugates were prepared in this way from
the same batch of thiolated antibody to allow for direct in
vtro and in vivo comparisons. The conjugates were then
dialysed against 0.1 M sodium acetate buffer, (Aldrich 22,987-
3), pH 5.0, for radiolabelling.
The chimeric B72.3 cDTPA conjugates were prepared as
follows. Chimeric B72.3 (15 mgml-') in 0.1 M sodium bicar-
bonate buffer pH 8.0 was vortexed for 5 min with a 5-fold
molar excess of cyclic DTPA anhydride (cDTPA) in dry
dimethylsulphoxide (DMSO). The mixture was maintained at
20-C for 30 min and then a small aliquot removed to deter-
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mine the number of DTPA molecules per antibody (Meares
et al., 1984). The remaining mixture was desalted into 0.1 M
sodium acetate buffer pH 5.0.
The buffers used in the preparation of the immunocon-
jugates contained 2 mM EDTA (except the radiolabelling
buffer) and were made from the highest grade reagents
available and made up using water from the Millipore Milli
Q SP reagent water system to prevent metal contamination
of the chelates.
The immunoconjugates were characterised and checked for
purity by high-performance liquid chromatography (HPLC)
gel filtration (DuPont Zorbax bioseries GF-250 column)
eluted with 0.2 M phosphate buffer pH 7.0 and by sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) under both reducing and non-reducing conditions.
The immunoreactivity of the conjugates was determined by
enzyme-linked immunosorbent assay (ELISA) as previously
described (King et al., 1992).
"'In labelling ofcB723 conjugates
Indium-l11 chloride (Amersham; 2mCi, volume 200 LI) in
40mM hydrochloric acid was added to the immunocon-
jugates (at 5mgml-') in 0.1 M sodium acetate pH 5.0 to give
a potential specific activity of 1.2;LCin-g1. The mixtures
were left at 20C for lSmin and then quenched by the
addition of free DTPA to 5 mM. The extent of indium bind-
ing and integrity of the conjugates was determined by
injecting an aliquot onto an HPLC gel filtration column
connected in series to a UV detector and radiochemical
detector. The HPLC mobile phase was 0.2 M sodium phos-
phate pH 7.0 containing 5 mM DTPA eluted at a flow rate of
1.0 ml min-'. The radiolabelled cB72.3 conjugates were
purified by HPLC gel filtration under the same conditions,
followed by buffer exchange into phosphate-buffered saline
(PBS). In the case of the 12N4 macrocycle the HPLC-
purified material was maintained overnight at 20C in the
presence of 5 mM DTPA to remove loosely bound "1'In,
followed by buffer exchange into phosphate-buffered saline
(PBS).
The radiochemical purity of each radiolabelled conjugate
was determined by reinjecting an aliquot of each preparation
onto a DTPA-stripped HPLC gel filtration column run under
the same conditions. This was corroborated by an instant
thin-layer chromatography (ITLC) assay (Meares et al.,
1984), in which aliquots of the radiolabelled immunocon-
jugates were spotted in duplicate onto preactivated (heated to
1 I0C for 30min) mILC plates (Gelman Sciene), and de-
veloped with 0.1 M sodium citrate buffer pH 5.0. The strips
were cut into four pieces and counted using an LKB gamma
counter. In this assay free "'In was complexed, migrating
with the solvent front, whereas antibody-bound "'In
remained at the origin. The radiochemical purity was cal-
culated as the percentage of counts rmaining at the origin
divided by the total counts (from the four pieces) multiplied
by 100.
Animal tumour model studies
The human colorectal carcinoma line LS- 74T expresses high
levels of TAG-72 (the antigen for B72.3) when grown as a
solid tumour, and the animal xenograft model has been
described in detail elsewhere (Colcher et al., 1986; Lundy et
al., 1986; Brown et al., 1987; Esteban et al., 1987).
Groups of four female nude mice bearing subcutaneous 2-
to 3-week-old LS-174T xenografts on the flanks were injected
i.v. into the tail vein with 20-25IACi 16 g-' "'In cB72.3
immunoconjugate. Groups of animals were killed at intervals
for the collection of tissue samples, which were weighed,
dissolved in 7M potassium hydroxide and counted in a
gamma counter (LKB model 1270). Tissue uptake was cal-
culated as the mean percentage of the injected dose per gram
of tissue (% IDg-') from a group of four mice.BIODISTRIBUTION OF "'In-LABELLED MACROCYCLES IN TUMOUR-BEARING MICE 37
Results
Preparation ofinmunoconjugates andradiolabelling
For correct interpretation of in vivo data it is important to
characterise the immunoconjugates prepared. The number of
chelation groups for "'In was controlled at 0.5-1.0 in each
case to minimise any possible damage to the antibody as
modification with high levels ofcDTPA or 2-iminothiolane is
known to cause loss of immunoreactivity and often aggrega-
tion of the antibody (Paik et al., 1985; Sakahara et al., 1985).
For the macrocycle and the CT-DTPA conjugates, this was
achieved by reacting a small aliquot of the antibody with
4,4'-dithiodipyridine (DTDP) immediately after 2-imino-
thiolane modification to determine the number of generated
thiol groups and then again on another aliquot after reaction
with the appropriate maleimide linker to determine how
many thiol groups were remaining. The difference in the
number of titratable thiols in the two assays gave the number
of chelates per antibody. Controls were carried out to show
that in the absence of the linkers the loss of thiols by
oxidation was minimal. For the cDTPA conjugate the
number of chelates per antibody was determined by a
radiolabelling HPLC/ITLC assay (Meares et al., 1984).
Preparation of conjugates with CT-DTPA, 9N3 and 12N4
resulted in only very low levels of aggregation visible on
HPLC (less than 5% in each case). SDS-PAGE analysis of
these conjugates also showed no difference in the banding
pattern to the unmodified antibody when examined under
non-reducing conditions on an 8% gel or reducing conditions
on a 12% gel. HPLC analysis of the cDTPA conjugate also
revealed less than 5% aggregate present by HPLC, but in
this case some high molecular weight forms were noticed by
SDS-PAGE, suggesting that more damage was caused to the
antibody during the preparation of this conjugate. The
antigen-binding ability of the immunoconjugates was
unchanged from the unmodified antibody, probably as a
result of keeping the number of chelation groups attached to
a minimum (>0.5, <1.0). Further purification of the
immunoconjugates was not carried out at this stage as the
small amounts of aggregate present were removed by HPLC
after radiolabelling.
Stability of the labelled preparations was considered to be
very important, and as a result stripping experiments using
DTPA were initially performed on both the free maleimide
derivatives of 9N3 and 12N4 as well as the immunocon-
jugates. The derivatives were labelled with "'In and purified
by injection onto HPLC ion exchange in series with a radio-
chemical detector and eluted isocratically with 70%
water-20% 1 M ammonium acetate, pH 6.5-10% acetronit-
rile. The labelled linkers were then incubated in 5 mM DTPA
for up to 24 h at room temperature, and the loss of the "'IIn
from the macrocycle was monitored by the increase in the
"'In-DTPA peak on HPLC. There was a loss of <3% of
"'In from the 9N3 linker, whereas there was >40% loss
from the 12N4 linker over the same time period.
A similar phenomenon to that seen with the free macro-
cycle derivatives was observed with the "'In-labelled 9N3 and
12N4 immunoconjugates when the HPLC-purified samples
(in 0.2 M sodium phosphate-5 mM DTPA, pH 7.0) were
assessed for radiochemical purity. One IgG-associated peak
for the 9N3 conjugate was seen, whereas two peaks were seen
for the 12N4 conjugate found to be IgG and low molecular
weight material ("'In-DTPA), the latter accounting for 25%
of the total counts. Figure 2 shows the HPLC/radiochemical
detector profiles obtained at various stages in the preparation
of the final immunoconjugate. Hence, the 12N4 conjugate
was less stable, with 25% of the activity dissociating from the
antibody after overnight incubation. Removal of the "'In-
DTPA from the 12N4 conjugate preparation by G-25 Sepha-
dex chromatography resulted in a stable conjugate with no
further loss of "'In. The incubation was continued for a
further period of 3 days, but no further loss of "'lindium was
seen.
Experiments were also performed in which non-thiolated
cB72.3 was incubated with the maleimide derivative of both
the9N3 and 12N4 linkers and then labelled with "'In in the
same way. HPLC/radiochemical detector analysis showed
that the counts were only associated with low molecular
weight material, that is "'In-12N4 and "'In-DTPA (data not
shown). This meant that there was no non-specific attach-
ment of the chelates to the antibody.
These data suggested that the 12N4 macrocycle binds "'In
in two forms, one of which is loosely bound and can be
stripped from the conjugate by incubation in DTPA and the
other of which is apparently stable. Indium-111 binding by
the 12N4 macrocycle has been examined by 13C nuclear
magnetic resonance (NMR) studies in both acetate and suc-
cinate buffers (pH 5-6), but only one complex was seen (D.
Parker, unpublished data). In view of these results, the label-
ling procedure for the 12N4 conjugate was modified to in-
clude an overnight DTPA stripping step prior to purification
for in vivo use. Similar stripping studies with the CT-DTPA
and cDTPA immunoconjugates revealed that all of the
activity was IgG bound. The final radiolabelling efficiencies
are shown in Table I. The initial uptake of "'In by the 12N4
macrocycle conjugate (-60%) was lower than for the 9N3,
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Fgwe 2 HPLC/radiochemical detector profiles of "'In-labelled
cB72.3-9N3 and cB72.3-12N4 conjugates and before and after
HPLC purification, ilhustrating the requirement of the DTPA
stripping step for the 12N4 conjugate. a, "'In-DTPA at
12.22 min; b, "'In-cB72.3-9N3 before HPLC purification, at
7.59min with <5% aggregate peak; c, "'In-cB72.3-12N4 before
HPLC purification, at 7.59 min with a free "'In-DTPA peak at
12.22 min; d, "'In-cB72.3-9N3 after HPLC purification, at
8.31 min showing removal of the aggregate peak and free "'In-
DTPA; e, "'In-cB72.3-12N4 after HPLC purification followed
by incubation in 5 mm DTPA, pH 7.0, overnight; f, "'In-
cB72.3-12N4 prepared as in e after buffer exchange into PBS to
remove "'In-DTPA prior to injection into mice.
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cDTPA and CT-DTPA chelates and dropped further to 35%
after the stripping step.
All labelled immunoconjugates were purified by prepar-
ative HPLC before use for in vivo studies so that the small
amounts of aggregate and free indium present were removed,
allowing the preparation of very high-quality labelled
immunoconjugates. The resulting preparations contained no
detectable aggregate or free "'In by duplicate HPLC (Figure
2) and ITLC assays. SDS-PAGE/autoradiography of the
labelled preparations also revealed a high degree of purity.
The bands on the autoradiograph corresponded to the
Coomassie blue-stained bands on SDS-PAGE.
Biodistribution in nude mice bearing LS]74Txenografts
The tissue distributions of cDTPA, CT-DTPA and 9N3 con-
jugates were compared at 24, 48 and 144 h. The results show
Table I Radiolabelling effcincy of immunoconjugtes
Raiolabelling efficienc
Immunoconjugate (final) (%)
cB72.3-cDTPA 86
cB72.3 CT-DTPA 90
cB72.3-9N3 95
cB72.3-12N4 35
Radiolabelling was carried out as described in the text and the
efficiency determined by HPLC/radiochemical detector. For cDTPA,
CT-DTPA and 9N3 conjugtes radiolabelling was performed in
0.1 M sodium acetate, pH 5.0, at 20C for 15 miin, quenched by the
addition of 5 mM DTPA and HPLC purfied. For the 12N4 con-
jugate radiolabelling was carried out as above except that an over-
night stripping step in 5 mM DTPA was included after the HPLC
purification.
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Table I Comparative biodistribution of ...In-labelled cB72.3
conjugates in LS-174T tumour-bearing mice
Tissue 9N3 cDTPA CT-DTPA
24h
Blood 13.33 (0.62) 9.34 (0.68) 15.02 (1.43)
Liver 4.40 (0.38) 4.95 (0.67) 4.83 (0.65)
Kidney 13.30 (0.80) 10.32 (0.71) 18.57 (0.43)
Lung 5.% (0.19) 4.70 (0.73) 6.52 (0.63)
Spleen 3.30 (0.18) 3.31 (0.38) 3.44 (0.21)
Colon 1.61 (0.06) 1.53 (0.14) 1.61 (0.11)
Muscle 1.49 (0.13) 1.73 (0.31) 1.34 (0.15)
Femur 1.61 (0.06) 1.49 (0.17) 1.83 (0.15)
Tumour 14.48 (1.48) 10.75 (0.52) 13.44 (1.82)
48h
Blood 12.87 (2.12) 8.39 (0.57) 14.16 (1.82)
Liver 3.94 (0.47) 5.79 (0.29) 4.77 (0.30)
Kidney 17.39 (1.23) 14.20 (0.79) 35.54 (1.87)
Lung 5.58 (0.97) 4.37 (0.24) 6.45 (0.28)
Spleen 3.49 (0.42) 3.85 (0.13) 3.77 (0.05)
Colon 1.35 (0.32) 2.23 (0.11) 1.66 (0.09)
Muscle 1.17 (0.20) 1.40 (0.17) 1.39 (0.21)
Femur 1.68 (0.21) 2.63 (0.16) 2.01 (0.14)
Tumour 22.88 (1.76) 12.79 (1.56) 18.20 (0.94)
144h
Blood 3.87 (2.12) 2.99 (0.67) 6.78 (0.67)
Liver 3.18 (0.47) 5.81 (0.20) 3.27 (0.21)
Kidney 10.68 (1.23) 10.63 (1.17) 22.66 (2.44)
Lung 2.26 (0.97) 3.03 (0.31) 3.50 (0.25)
Spleen 2.63 (0.42) 3.76 (0.37) 3.77 (0.36)
Colon 0.61 (0.32) 1.24 (0.11) 3.77 (0.36)
Muscle 0.85 (0.20) 1.45 (0.36) 0.82 (0.04)
Femur 1.00 (0.21) 1.94 (0.43) 1.28 (0.09)
Tumour 14.45 (1.76) 8.33 (0.90) 15.50 (2.60)
Results expressed as the mean per cent injected dose per gram of
tissue (standard error, n = 4).
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Figwe 3 Graphical representation of tissue-to-blood ratios of "'In-labelled cB72.3 conjugates in LS-174T tumour-bearing mice: a,
liver; b, femur, c, colon; d, spleen for 9N3 (from Table II). ( ), 9N3 (from Table III) ( ), cDTPA; ( O ), CT-DTPA ( )
and 12N4 ( l ). In each case the ratios caculated from individual mouse data are plotted as mean per cent injected dose per
gram of tissue divided by mean per cent injected dose of blood. Error bars indicate standard errors of the mean.
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(Table II) that the tumour uptake was significantly higher for
the 9N3 conjugate at each time point (P<0.05) compared
with the cDTPA conjugate, but similar to the CT-DTPA
conjugate. This was a result of the significantly lower blood
levels (P<0.05) for the cDTPA conjugate. The liver levels
were low for all three conjugates but differed significantly for
cDTPA at 144 h (P<0.01). Another significant difference in
biodistribution was seen in the femur, where the levels were
higher for the cDTPA conjugate (P<0.05). Levels of activity
in the kidney were relatively high and variable with this
chimeric antibody for all chelates, and especially for CI-
DTPA. This is known to be a particular property in four
known cases (three unpublished) of human IgG4 antibodies
resulting from the proportion of human IgG4 which does not
fully form its hinge disulphide bonds (Angal et al., 1993, and
unpublished data). Overall the most favourable distribution
was observed for the 9N3 conjugate.
A further biodistribution study was then undertaken to
compare the tissue distribution of "'In-labelled 9N3 macro-
cycle conjugate with a 12N4 macrocycle conjugate labelled
with "'In and stripped with DTPA as described. The results
at 24, % and 144 h are shown in Table III. In this experi-
ment the difference between the two conjugates was not so
pronounced. However, the differences were mainly seen at
144 h, when the liver and the femur levels were significantly
higher for the 12N4 conjugate (P<0.05).
To allow comparison of tissues without the contribution of
differences in blood-associated activity, the tissue-to-blood
ratios were calculated (% ID g-' tissue divided by % IDg-'
blood). The ratios were obtained by calculating the means
(and standard error) of the ratios of individual mice in each
group. These ratios emphasised the difference between the
chelates, especially with respect to the spleen, liver, colon and
femur (Figure 3), instability of the cDTPA conjugate being
seen especially at the longer time points. Some variation was
observed in the blood levels between the different cB72.3-9N3
chelates used in the two experiments, however this was
Tab m Comparative biodistribution of "'.In-labelled cB72.3
macrocyclic conjugates in LS-174T tumour-bearing mice
Tissue 9N3 12N4
24 h
Blood 9.84 (0.81) 13.24 (2.34)
Liver 3.82 (0.54) 4.47 (0.50)
Kidney 11.99 (1.25) 16.86 (1.51)
Lung 4.73 (0.71) 5.27 (0.80)
Spleen 2.64 (0.28) 3.23 (0.25)
Colon 1.38 (0.18) 1.% (0.21)
Muscle 1.21 (0.12) 1.89 (0.19)
Femur 1.43 (0.22) 2.17 (0.31)
Tumour 10.36 (1.01) 9.59 (0.53)
96h
Blood 7.28 (0.35) 6.30 (0.91)
Liver 3.70 (0.20) 6.40 (0.63)
Kidney 15.29 (1.93) 15.14 (1.75)
Lung 3.71 (0.38) 4.14 (0.77)
Spleen 3.11 (0.42) 4.48 (0.60)
Colon 1.05 (0.09) 1.46 (0.14)
Muscle 1.00 (0.26) 0.84 (0.21)
Femur 1.21 (0.09) 1.94 (0.32)
Tumour 12.72 (1.54) 10.44 (1.32)
144h
Blood 4.85 (0.73) 4.83 (0.44)
Liver 3.62 (0.19) 5.41 (0.65)
Kidney 12.76 (1.90) 14.62 (1.30)
Lung 3.22 (0.46) 3.06 (0.19)
Spleen 3.08 (0.32) 3.94 (0.22)
Colon 0.89 (0.08) 1.45 (0.27)
Muscle 0.94 (0.16) 1.33 (0.09)
Femur 0.99 (0.15) 1.59 (0.25)
Tumour 11.31 (1.03) 9.69 (0.78)
Results expressed as mean per cent injected dose per gram of
tissue (standard error, n = 4).
largely due to the variation within groups of mice. When the
tissue-to-blood ratios were examined it was evident that there
was no real difference.
The tumour accumulation was directly related to the blood
clearance as evidenced by the tumour-to-blood ratios (cal-
culated from individual mouse data), which were similar for
all of the chelates. There was some evidence of higher
tumour-to-tissue ratios for the 9N3 conjugate compared with
the 12N4 conjugate in the liver, colon and femur, especially
at the longer time point (144h, Figure 4).
Eiscossom
The aim of this work was to identify the best method for the
attachment of "'In to antibodies for tumour imaging pur-
poses and to compare with the relevant clinical standard,
cDTPA. To achieve this, several factors need to be taken into
account, including the ease and speed of preparation of the
labelled antibody, the radiolabelling efficiency and the in vivo
biodistribution. We have shown that all of the conjugates
prepared here are capable of being labelled with "'In, with
both the bifunctional DTPA derivative CIT-DTPA and 9N3
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Figwe 4 Graphical representation of tumour to tissue ratios of
"'In-labelled cB72.3 conjugates in LS-174T tumour-bearing mice
at a, 24h and b, 144 h for 9N3 (from Table II), ( ) 9N3
(from Table III) ( M ), cDTPA ( M ), CT-DTPA ( ) and
12N4 ( = ). In each case the ratios calcuated from individual
mouse data are plotted as the mean per cent injected dose per
gram of tumour divided by the mean per cent injected dose per
gram of tissue. Error bars indicate standard errors of the
mean.
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macrocycle labelling to particularly high efficiency. The 12N4
macrocycle is somewhat more difficult to use with "'In
because of the need for a DTPA stripping step to remove
loosely bound "'In.
Great care was taken in the preparation of labelled con-
jugates for in vivo studies. They were prepared by protocols
designed to minimise antibody damage and purified by
HPLC to produce high-quality labelled conjugates. This has
been reported to improve biodistribution and consequently
scintigraphic images (Esteban et al., 1987). Indeed, as a result
our own biodistribution data with the cDTPA conjugate
were seemingly better than published data obtained with the
murine version of the B72.3 antibody (Brown et al., 1987;
Esteban et al., 1987).
The "'In-cB72.3-9N3 conjugate was shown to be more
stable in vivo than cDTPA, as evidenced by significantly
lower liver, femur and colon uptake. This was particularly
emphasised by the tissue-to-blood ratios, which increased
with time for the cDTPA conjugate as "'In was lost from the
blood and accumulated in a range of tissues. The bifunc-
tional DTPA derivative, CT-DTPA, also showed an im-
proved biodistribution over cDTPA, as expected by
comparison with other substituted DTPA chelates (Roselli et
al., 1989). Comparison of CT-DTPA and the 9N3 macro-
cycle biodistributions showed them to be very similar, with
the major difference being the lower kidney levels for 9N3.
Both CT-DTPA and the 9N3 macrocycle are attractive as
chelators for "'In, with 9N3 being preferable.
The biodistribution of the 12N4 macrocycle conjugate
showed poorer tumour-to-tissue ratios than the 9N3 macro-
cycle conjugate, however the data showed that both of these
macrocycles are capable of "'In chelation in a stable form.
The attraction of using the 12N4 macrocycle for "'In is that
this macrocycle can also chelate 9'Y in a very stable form
with improved biodistribution over cDTPA and CT-DTPA
(Meares et al., 1990; Harrison et al., 1991). This would allow
the use of the same antibody conjugate for both imaging
with "'In and therapy with 9'Y. However, the more difficult
and time-consuming labelling procedure to achieve stable
"'In uptake by 12N4 makes this alternative less attractive.
The importance of this procedure is emphasised by the work
of Snook et al. (1991), who found that high liver levels of
activity were seen (similar to those seen with cDTPA) when a
similar derivative of 12N4 was tested without a DTPA strip-
ping step in the labelling procedure.
Some preliminary clinical studies have been reported using
a similar 12N4 macrocycle to that used in this study,
attached to the antibodies HMFG1 and a humanised version
of H17E2 (Hird et al., 1991; Kosmas et al., 1992). In these
studies an immune response was generated by the patients to
the macrocycle, which appeared to act as a hapten when
attached to the antibody. The macrocyclic ligand used was
lined to the antibody through a benzyl-containing structure,
and is therefore a very different type of structure to those
used here, in which no aromatic rings are present. In addi-
tion, high levels of aggregate (up to 16%) were present in the
preparations used by Kosmas et al. (1992). However, the
immunogenicity of the 9N3 and 12N4 macrocycic conjugates
used in this report remains to be evaluated.
Overall, the malemide derivative of the 9N3 macrocycle is
an ideal reagent for the attachment of "'In to antibodies in a
stable form, it can be attached in a simple procedure without
causing antibody damage, can be labelled to high efficiency
and gives rise to a very stable conjugate in biodistribution
studies. Indeed, a preliminary report of clinical data with this
reagent attached to the antibody SM3 has revealed superior
tumour imaging to that obtained with the same antibody
labelled with DTPA (Granowska et al., 1991). The combina-
tion of stable attachment methods for radioisotopes such as
the macrocyclic ligands reported here with recombinant
humanised antibodies, which may allow repeat dosing
through reduction of the immune response (Adair, 1992),
should allow the development of a new generation of
radiolabelled antibody conjugates for tumour imaging and
therapy.
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Abbreviabtoa cDTPA. cyclic diethylenetriaminepentaacetic acid
anhydride; % IDg-1, mean percentage injected dose per gram;
CT-DTPA, C-linked derivative of DTPA; 9N3, c-functionalised
derivative of 1,4,7-triazacyclonanetriacetic acid; 12N4, C-func-
tionalised derivative of 1,4,7,10-tetraazacyclododecanetetraacetic
acid, RI, radiolocalisation indices (percentage injected dose per gram
tumour divided by percentage injected dose per gram tissue); ITLC,
instant thin-layer chromatography; DTDP, 4,4'-dithiodipyridine;
DMSO, dimethylsulphoxide.
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